Business Description
Replimune Group Inc
NAICS : 325412
SIC : 2834
ISIN : US76029N1063
Description
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.18 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.36 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -23.5 | |||||
| 3-Year EPS without NRI Growth Rate | -27.1 | |||||
| 3-Year FCF Growth Rate | -27.7 | |||||
| 3-Year Book Growth Rate | -17.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 16.78 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.05 | |||||
| 9-Day RSI | 59.38 | |||||
| 14-Day RSI | 58.08 | |||||
| 6-1 Month Momentum % | 72.6 | |||||
| 12-1 Month Momentum % | -24.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.46 | |||||
| Quick Ratio | 13.46 | |||||
| Cash Ratio | 13.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.7 | |||||
| Shareholder Yield % | -8.07 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -49.96 | |||||
| ROA % | -40.41 | |||||
| ROIC % | -331.21 | |||||
| 3-Year ROIIC % | -1977.55 | |||||
| ROC (Joel Greenblatt) % | -408.4 | |||||
| ROCE % | -41.98 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.88 | |||||
| Price-to-Tangible-Book | 1.88 | |||||
| EV-to-EBIT | -2.04 | |||||
| EV-to-EBITDA | -2.07 | |||||
| EV-to-Forward-Revenue | 12.55 | |||||
| EV-to-FCF | -2.25 | |||||
| Price-to-Net-Current-Asset-Value | 2.16 | |||||
| Price-to-Net-Cash | 2.23 | |||||
| Earnings Yield (Greenblatt) % | -49.02 | |||||
| FCF Yield % | -24.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:REPL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Replimune Group Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.27 | ||
| Beta | 0.46 | ||
| Volatility % | 90.65 | ||
| 14-Day RSI | 58.08 | ||
| 14-Day ATR ($) | 0.594515 | ||
| 20-Day SMA ($) | 11.581 | ||
| 12-1 Month Momentum % | -24.78 | ||
| 52-Week Range ($) | 4.92 - 15.025 | ||
| Shares Outstanding (Mil) | 68.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Replimune Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Replimune Group Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Replimune Group Inc Frequently Asked Questions
What is Replimune Group Inc(REPL)'s stock price today?
The current price of REPL is $11.75. The 52 week high of REPL is $15.03 and 52 week low is $4.92.
When is next earnings date of Replimune Group Inc(REPL)?
The next earnings date of Replimune Group Inc(REPL) is 2024-11-07 Est..
Does Replimune Group Inc(REPL) pay dividends? If so, how much?
Replimune Group Inc(REPL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers